These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 4701794)

  • 1. A trial of prophylactic replacement therapy in haemophilia and Christmas disease.
    Ramsay DM; Parker AC
    J Clin Pathol; 1973 Apr; 26(4):243-7. PubMed ID: 4701794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
    Rizza CR; Kernoff PB; Matthews JM; McLennan CR; Rainsford SG
    Thromb Haemost; 1977 Feb; 37(1):86-90. PubMed ID: 320712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
    Roosendaal G; Lafeber FP
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis in children with haemophilia - the Polish experience.
    Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
    Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
    [No Abstract]   [Full Text] [Related]  

  • 7. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
    Nilsson IM; Berntorp E; Löfqvist T; Pettersson H
    J Intern Med; 1992 Jul; 232(1):25-32. PubMed ID: 1640190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C; Young G
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic factor replacement in hemophilia.
    Carcao MD; Aledort L
    Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to manage invasive procedures in children with haemophilia.
    Ljung RC; Knobe K
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia.
    Ho S; Gue D; McIntosh K; Bucevska M; Yang M; Jackson S
    Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Haemophilia A and haemophilia B. Are there relevant clinical differences?].
    Klamroth R; Orlovic M; Kubicek-Hofman C; Gottstein S
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S26-7. PubMed ID: 21042678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of facoor VIII and factor IX concentrates during surgery.
    George JN; Breckenridge RT
    JAMA; 1970 Nov; 214(9):1673-6. PubMed ID: 5536529
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 19. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial.
    Walsh PN; Rizza CR; Matthews JM; Eipe J; Kernoff PB; Coles MD; Bloom AL; Kaufman BM; Beck P; Hanan CM; Biggs R
    Br J Haematol; 1971 May; 20(5):463-75. PubMed ID: 4931484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.